BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35392965)

  • 21. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
    Setiady YY; Coccia JA; Park PU
    Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
    Butchar JP; Mehta P; Justiniano SE; Guenterberg KD; Kondadasula SV; Mo X; Chemudupati M; Kanneganti TD; Amer A; Muthusamy N; Jarjoura D; Marsh CB; Carson WE; Byrd JC; Tridandapani S
    Clin Cancer Res; 2010 Apr; 16(7):2065-75. PubMed ID: 20332325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
    Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
    J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
    Zhang D; Whitaker B; Derebe MG; Chiu ML
    MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
    White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
    J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis.
    Georgoudaki AM; Prokopec KE; Boura VF; Hellqvist E; Sohn S; Östling J; Dahan R; Harris RA; Rantalainen M; Klevebring D; Sund M; Brage SE; Fuxe J; Rolny C; Li F; Ravetch JV; Karlsson MC
    Cell Rep; 2016 May; 15(9):2000-11. PubMed ID: 27210762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
    J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
    Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
    J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.
    Nagelkerke SQ; Dekkers G; Kustiawan I; van de Bovenkamp FS; Geissler J; Plomp R; Wuhrer M; Vidarsson G; Rispens T; van den Berg TK; Kuijpers TW
    Blood; 2014 Dec; 124(25):3709-18. PubMed ID: 25352126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis.
    Kern N; Dong R; Douglas SM; Vale RD; Morrissey MA
    Elife; 2021 Jun; 10():. PubMed ID: 34080973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
    Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
    Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
    Teige I; Mårtensson L; Frendéus BL
    Front Immunol; 2019; 10():481. PubMed ID: 30930905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration.
    Bosco MC; Puppo M; Blengio F; Fraone T; Cappello P; Giovarelli M; Varesio L
    Immunobiology; 2008; 213(9-10):733-49. PubMed ID: 18926289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FcγRIIB as a key determinant of agonistic antibody efficacy.
    White AL; Beers SA; Cragg MS
    Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
    Lu H; Molony RD; Chen D; Jang S; Wolf B; Ewert S; Flaherty M; Xu F; Isim S; Shim Y; Dornelas C; Balke N; Leber XC; Scharenberg M; Koelln J; Choi E; Ward R; Johnson J; Calzascia T; Isnardi I; Williams JA; Lindenbergh PL; van de Donk NWCJ; Mutis T; Huet H; Lees E; Meyer MJ
    Mol Cancer Ther; 2020 Oct; 19(10):2089-2104. PubMed ID: 32847974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
    Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
    Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple bovine FcgammaRIIb sub-isoforms generated by alternative splicing.
    Firth MA; Chattha KS; Hodgins DC; Shewen PE
    Vet Immunol Immunopathol; 2010 May; 135(1-2):43-51. PubMed ID: 20005577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.